A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib
Phase of Trial: Phase I/II
Latest Information Update: 07 Jan 2019
Price : $35 *
At a glance
- Drugs Ruxolitinib (Primary) ; Erlotinib
- Indications Adenocarcinoma; Lung cancer; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 17 Oct 2017 Status changed from active, no longer recruiting to completed.
- 17 Apr 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 06 Sep 2016 Toxicity and efficacy results (n=22) published in the Journal of Thoracic Oncology.